Prophylactic recombinant thrombomodulin treatment prevents hepatic sinusoidal obstruction syndrome in high‐risk pediatric patients that undergo hematopoietic stem cell transplants. (12th July 2018)

• Record Type: Journal Article
• Authors: Yamamoto, Shohei; Toyama, Daisuke; Sugishita, Yumiko; Kaneko, Ryota; Okamoto, Naoko; Koganesawa, Masaya; Fujita, Sachio; Akiyama, Kosuke; Matsuno, Ryosuke; Isoyama, Keiichi
• Is Part Of: Pediatric transplantation. Volume 22:Number 7(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-07-12
• Subjects: hematopoietic stem cell transplants -- prophylaxis -- recombinant thrombomodulin -- sinusoidal obstruction syndrome; Transplantation of organs, tissues, etc. in children -- Periodicals; 617.95408305
• DOI: 10.1111/petr.13269
• Languages: English
• ISSNs: 1397-3142

Abstract

Abstract: Hepatic SOS is a potentially life‐threatening complication of conditioning for allogeneic HSCT. rTM is a new drug for treating DIC. We report our experience of the use of rTM as a prophylaxis against SOS in high‐risk pediatric patients that underwent HSCT. We evaluated the cases of 19 pediatric hematology and oncology patients who underwent HSCT at our institution between 2007 and 2016. The patients who received HSCT after 2012 (n = 8) were treated with rTM as a prophylaxis against SOS together with UDCA and LMWH, whereas the others (n = 11) were only treated with UDCA and LMWH. Although SOS occurred by post‐HSCT day 35 in 3 (27%) patients in the control group, SOS was not seen in the rTM group. Two of the former three patients suffered severe SOS, and one died of the condition. The mean peak level of PAI‐1 (a marker of endothelial damage) was significantly lower in the rTM group. rTM appears to be a safe prophylaxis for SOS. The present findings suggest that prophylactic rTM after HSCT might help to prevent SOS.